CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study participants and the immune T cells will be separated. T cells will be genetically modified in a laboratory at UNC-Chapel Hill to enable them to produce CD30 antibody. The modified T cells, called ATLCAR.CD30, will be able to target and attach to lymphoma cancer cells that carry the CD30 antigen. Once they are attached, the hope is that the T cells will attack and destroy the lymphoma cancer cells. To prepare th

Trial Details

NCT ID
NCT04083495
Phase
PHASE2
Sponsor
UNC Lineberger Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • ATLCAR.CD30 T cells
  • Bendamustine
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584
  • Winston-Salem, North Carolina, United States|36.09986,-80.24422

Key Eligibility Criteria

  • Written informed consent and HIPAA authorization for release of personal health information explained to, understood by and signed by the subject o…
  • Age ≥ 18 years at the time of consent.
  • Karnofsky score of \>60%
  • Histological or cytological evidence/confirmation of CD30+ peripheral T-cell lymphoma per the 2017 World Health Organization Classification of Haem…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →